Eupraxia Pharmaceuticals, Inc.

As of June 30, 2026, Eupraxia Pharmaceuticals, Inc. carries a market capitalization of 612.05M, placing it among publicly traded companies globally. Its enterprise value stands at 464.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eupraxia Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Eupraxia Pharmaceuticals, Inc. has 65.74M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Eupraxia Pharmaceuticals, Inc. maintains a current ratio of 16.00, meaning it holds 16.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -61.42, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 45.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Eupraxia Pharmaceuticals, Inc. recorded 78,059.39 in income tax expense. The company reported a pretax loss of -71.22M and -71.26M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Eupraxia Pharmaceuticals, Inc.'s stock has gained approximately 39.40% over the past 52 weeks. The 50-day moving average sits at 10.57, while the 200-day moving average is 10.21.

Over the twelve months ended June 30, 2026, Eupraxia Pharmaceuticals, Inc. generated - - in revenue and converted that into -71.26M in net income, yielding earnings per share of -1.35. EBITDA reached -80.54M, while operating income came in at -81.05M.

As of June 30, 2026, Eupraxia Pharmaceuticals, Inc. holds 189.69M in cash and equivalents against 2.62M in total debt, resulting in a net debt position of -74.40M. Total book value stands at 144.41M, with working capital of 182.02M providing operational flexibility.

Eupraxia Pharmaceuticals, Inc. produced -53.18M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.07M in capital expenditures, free cash flow totaled -54.25M - equivalent to -1.02 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.12, meaning Eupraxia Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Eupraxia Pharmaceuticals, Inc. has an Altman Z-Score of 23.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.